SCHEMBL25822735

SCHEMBL25822735

CN1CCN(c2ccc(Nc3nc4ccc(Br)cc4n4ccnc34)cc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPKAPK5 Q8IW41 1/20 0.52
EGFR P00533 10/20 0.50
MAPKAPK2 P49137 1/20 0.49
KDR P35968 2/20 0.46
HTR3E A5X5Y0 2/20 0.45
HTR3B O95264 2/20 0.45
HTR3A P46098 2/20 0.45
HTR3D Q70Z44 2/20 0.45
HTR3C Q8WXA8 2/20 0.45
MAPT P10636 1/20 0.44
MAPK1 P28482 1/20 0.44
AHR P35869 1/20 0.44
HTT P42858 1/20 0.44
EIF2AK2 P19525 1/20 0.44
IKBKB O14920 1/20 0.44
APP P05067 1/20 0.43
FYN P06241 1/20 0.42
FGFR1 P11362 1/20 0.42
ALK Q9UM73 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25822740 0.96 MAPKAPK5 (0.51) MAPKAPK5EGFRMAPKAPK2KDRHTR3E
SCHEMBL25822712 0.89 MAPT (0.58) MAPKAPK5MAPTMAPK1AHRHTT
SCHEMBL25822743 0.87 SYK (0.48) MAPKAPK5EGFRMAPTMAPK1AHR
SCHEMBL25822750 0.87 SYK (0.42) MAPKAPK5EGFRMAPTMAPK1AHR
SCHEMBL25823381 0.85 MAPKAPK5 (0.50) MAPKAPK5EGFRMAPKAPK2HTR3EHTR3B
SCHEMBL25822728 0.85 SYK (0.55)
SCHEMBL25822763 0.85 MAPT (0.46) MAPKAPK5MAPTMAPK1AHRHTT
SCHEMBL25822754 0.83 MAPKAPK5 (0.40) MAPKAPK5EGFRMAPTMAPK1AHR
SCHEMBL25822683 0.82 MAPKAPK5 (0.54) MAPKAPK5EGFRMAPKAPK2KDRFYN
SCHEMBL25822721 0.81 MAPT (0.55) MAPKAPK5MAPTMAPK1AHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219960-A1 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 OCUMENSION THERAPEUTICS (SUZHOU) CO., LTD. (CN) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219960-A1 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 SYK, KDR, FLT1 MAPKAPK5 216/4885EGFR 313/4885MAPKAPK2 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.